Stéphane Bancel, Moderna CEO (Christopher Goodney/Bloomberg via Getty Images)
November 2, 2023 07:39 AM EDTUpdated 01:32 PM
Pharma

Mod­er­na looks past post-Covid 'low point' at a fu­ture based on com­bi­na­tion vac­cines, can­cer in­di­ca­tions

Nicole DeFeudis

Editor

The Covid boom is over at Mod­er­na.

On Thurs­day, the biotech said it was brac­ing for sales to “hit a low point” in 2024 as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times